DoW Peer Reviewed Cancer, Clinical Trial Award
About
Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e. g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III. • If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial. • Applications are required to include patient advocates. • Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.
The DoW Peer Reviewed Cancer, Clinical Trial Award supports researchers and organizations conducting clinical trials with significant potential to advance cancer treatment and management. This award mechanism is designed for teams ready to move promising interventions from concept to human testing, spanning from early-stage proof-of-concept trials (phase 0, pilot, first-in-human) through large-scale efficacy studies (phase III). Funded projects may evaluate new pharmaceutical agents, biologics, medical devices, clinical guidance protocols, and emerging technologies. This award is ideal for cancer researchers, clinical institutions, and research organizations seeking to accelerate the translation of innovations into patient care. The program emphasizes collaborative, patient-centered approaches by requiring patient advocate involvement in all applications. If your proposed trial requires regulatory approval through an IND application, IDE, or equivalent, you must submit the regulatory application by the program deadline. All preclinical work must be completed before the award begins. This is an excellent opportunity for serious clinical investigators positioned to conduct rigorous, impactful cancer trials that can meaningfully improve patient outcomes across diverse cancer types and treatment approaches.
Funding Facts
● Applications openDeadline
October 5, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by cycle
Deadline
2026-10-05
Grant Type
federal
Application Cycle
Annual
Best For
Cancer researchers, clinical institutions, and research organizations conducting clinical trials on cancer treatments and management approaches
Frequently Asked Questions
Who is eligible for DoW Peer Reviewed Cancer, Clinical Trial Award?
Specific eligibility criteria are not provided in the current program summary. For detailed eligibility requirements regarding institutional type, investigator qualifications, and organizational status, please visit the official Department of Defense Congressionally Directed Medical Research Programs (CDMRP) website or contact the program directly.
How much funding does DoW Peer Reviewed Cancer, Clinical Trial Award provide?
Funding amounts are not specified in the current program information. Award amounts typically vary based on project scope, trial phase, and trial duration. Consult the official program announcement or CDMRP website for specific funding ranges for the FY26 funding cycle.
How do I apply for DoW Peer Reviewed Cancer, Clinical Trial Award?
Applications for the FY26 award cycle must be submitted by October 5, 2026. Applications must include a clinical trial component and patient advocate participation. If your trial requires regulatory approval (IND, IDE, or equivalent), submit the regulatory application to the appropriate agency by the same deadline. For detailed application instructions, submission portal access, and required documentation, visit the official CDMRP website.
What can DoW Peer Reviewed Cancer, Clinical Trial Award funding be used for?
Funding supports the implementation of clinical trials evaluating new products, pharmacologic agents (drugs or biologics), medical devices, clinical guidance, and emerging approaches and technologies for cancer treatment and management. Trials may range from phase 0 through phase III. All preclinical work must be completed before the award begins; animal studies are not permitted under this mechanism.
Last updated: July 5, 2026